HWM
VRTX icon

HB Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

HB Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.59M Buy
10,287
+815
+9% +$380K 0.03% 266
2025
Q4 		$4.29M Buy
9,472
+792
+9% +$341K 0.03% 275
2025
Q3 		$3.4M Sell
8,680
-1,903
-18% -$795K 0.02% 312
2025
Q2 		$4.71M Sell
10,583
-73
-0.7% -$33.6K 0.04% 238
2025
Q1 		$5.17M Buy
10,656
+1,889
+22% +$880K 0.04% 224
2024
Q4 		$3.53M Buy
8,767
+392
+5% +$182K 0.04% 203
2024
Q3 		$3.9M Buy
8,375
+360
+4% +$173K 0.04% 181
2024
Q2 		$3.76M Buy
8,015
+2,585
+48% +$1.12M 0.04% 179
2024
Q1 		$2.27M Buy
5,430
+1,528
+39% +$646K 0.03% 225
2023
Q4 		$1.59M Buy
3,902
+276
+8% +$102K 0.02% 256
2023
Q3 		$1.26M Buy
3,626
+1,180
+48% +$413K 0.02% 274
2023
Q2 		$861K Buy
2,446
+268
+12% +$90.3K 0.01% 311
2023
Q1 		$686K Buy
2,178
+298
+16% +$89.4K 0.01% 350
2022
Q4 		$543K Buy
1,880
+245
+15% +$74.7K 0.01% 377
2022
Q3 		$473K Buy
1,635
+284
+21% +$81.7K 0.01% 346
2022
Q2 		$381K Buy
+1,351
New +$362K 0.01% 395

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HB Wealth Management's VRTX Position: Q1 2026 in Review

HB Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 8.6% in Q1 2026, buying an estimated $380K and bringing the position to 10,287 shares worth $4.59M. The position accounts for 0.03% of the portfolio, ranked #266.

HB Wealth Management first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $5.17M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • HB Wealth Management held 10,287 shares of Vertex Pharmaceuticals worth $4.59M as of Q1 2026.
  • HB Wealth Management bought 815 Vertex Pharmaceuticals shares in Q1 2026, an estimated $380K.
  • Vertex Pharmaceuticals made up 0.03% of HB Wealth Management's portfolio in Q1 2026, its #266 holding.
  • HB Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • HB Wealth Management's Vertex Pharmaceuticals position peaked at $5.17M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on HB Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.